# Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507

Study · id `cardio:ct-nct04772443` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04772443](<https://clinicaltrials.gov/study/NCT04772443>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04772443

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 280 participants.

## Technical summary

Registry record NCT04772443. Randomized; quadruple masking; primary purpose treatment. Start 2021-02 (anticipated); primary completion 2022-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 280 participants (planned count; ClinicalTrials.gov record NCT04772443, source copy `cardio:ctgov-nct04772443-2021-02-26`, retrieved 2026-10-31)
- Planned start: 2021-02 (anticipated) (ClinicalTrials.gov record NCT04772443, source copy `cardio:ctgov-nct04772443-2021-02-26`, retrieved 2026-10-31)
- Primary completion: 2022-12 (anticipated) (ClinicalTrials.gov record NCT04772443, source copy `cardio:ctgov-nct04772443-2021-02-26`, retrieved 2026-10-31)
- Completion: 2022-12 (anticipated) (ClinicalTrials.gov record NCT04772443, source copy `cardio:ctgov-nct04772443-2021-02-26`, retrieved 2026-10-31)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04772443-2021-02-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluate the Efficacy and Safety of DWJ1506 and DWJ1507
- Condition: Dyslipidemias
- Intervention (Drug): DWJ1506
- Intervention (Drug): DWJ1507
- Intervention (Drug): DWC202011
- Intervention (Drug): DWJ1177
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 3a0695cb476509b5d6c81ec9e3e7184d254853ef23e6a34b89cb0a54e214313f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
